Compare EVTV & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTV | CTXR |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.6M | 18.9M |
| IPO Year | 2014 | 2010 |
| Metric | EVTV | CTXR |
|---|---|---|
| Price | $1.72 | $0.85 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 904.0K | 405.2K |
| Earning Date | 04-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,939,008.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $147.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 217.58 | N/A |
| 52 Week Low | $0.15 | $0.63 |
| 52 Week High | $5.07 | $2.38 |
| Indicator | EVTV | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 49.68 | 53.91 |
| Support Level | $1.63 | $0.66 |
| Resistance Level | $2.40 | $0.98 |
| Average True Range (ATR) | 0.14 | 0.07 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 45.54 | 68.21 |
Envirotech Vehicles Inc is a provider of purpose-built zero-emission electric vehicles focused on reducing the total cost of vehicle ownership and helping fleet operators unlock the benefits of green technology. It recognizes revenue from the sales of zero-emission electric vehicles and vehicle maintenance and inspection services. The Company serves commercial and last-mile fleets, school districts, public and private transportation service companies and colleges and universities to meet the increasing demand for light to heavy-duty electric vehicles.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.